- Home
- REVB vs RDHL Comparison
REVB vs RDHL Comparison
Compare REVB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- RDHL
- Stock Information
- Founded
- REVB 2020
- RDHL 2009
- Country
- REVB United States
- RDHL Israel
- Employees
- REVB N/A
- RDHL N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- RDHL Health Care
- Exchange
- REVB Nasdaq
- RDHL Nasdaq
- Market Cap
- REVB 3.4M
- RDHL 3.9M
- IPO Year
- REVB N/A
- RDHL N/A
- Fundamental
- Price
- REVB $1.35
- RDHL $1.54
- Analyst Decision
- REVB
- RDHL
- Analyst Count
- REVB 0
- RDHL 0
- Target Price
- REVB N/A
- RDHL N/A
- AVG Volume (30 Days)
- REVB 195.9K
- RDHL 1.4M
- Earning Date
- REVB 11-07-2025
- RDHL 09-05-2025
- Dividend Yield
- REVB N/A
- RDHL N/A
- EPS Growth
- REVB N/A
- RDHL N/A
- EPS
- REVB N/A
- RDHL N/A
- Revenue
- REVB N/A
- RDHL $9,550,000.00
- Revenue This Year
- REVB N/A
- RDHL $381.91
- Revenue Next Year
- REVB N/A
- RDHL N/A
- P/E Ratio
- REVB N/A
- RDHL N/A
- Revenue Growth
- REVB N/A
- RDHL 157.62
- 52 Week Low
- REVB $1.15
- RDHL $1.06
- 52 Week High
- REVB $60.48
- RDHL $8.75
- Technical
- Relative Strength Index (RSI)
- REVB 42.07
- RDHL 42.97
- Support Level
- REVB $1.23
- RDHL $1.50
- Resistance Level
- REVB $1.38
- RDHL $1.90
- Average True Range (ATR)
- REVB 0.08
- RDHL 0.15
- MACD
- REVB 0.03
- RDHL -0.03
- Stochastic Oscillator
- REVB 57.65
- RDHL 6.25
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.